Extracellular Vesicles as Drug Delivery Systems in Cancer
Hernandez-Oller, Laia (Hospital Universitari Vall d'Hebron)
Seras-Franzoso, Joaquin (Vall d'Hebron Institut de Recerca (VHIR))
Andrade, Fernanda (Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina)
Rafael, Diana (Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina)
Abasolo, Ibane (Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina)
Gener, Petra (Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina)
Schwartz, Simon (Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina)
Universitat Autònoma de Barcelona

Fecha:	2020
Resumen:	Within tumors, Cancer Stem Cell (CSC) subpopulation has an important role in maintaining growth and dissemination while preserving high resistance against current treatments. It has been shown that, when CSCs are eliminated, the surrounding Differentiated Cancer Cells (DCCs) may reverse their phenotype and gain CSC-like features to preserve tumor progression and ensure tumor survival. This strongly suggests the existence of paracrine communication within tumor cells. It is evidenced that the molecular crosstalk is at least partly mediated by Extracellular Vesicles (EVs), which are cell-derived membranous nanoparticles that contain and transport complex molecules that can affect and modify the biological behavior of distal cells and their molecular background. This ability of directional transport of small molecules prospects EVs as natural Drug Delivery Systems (DDS). EVs present inherent homing abilities and are less immunogenic than synthetic nanoparticles, in general. Currently, strong efforts are focused into the development and improvement of EV-based DDS. Even though EV-DDS have already reached early phases in clinical trials, their clinical application is still far from commercialization since protocols for EVs loading, modification and isolation need to be standardized for large-scale production. Here, we summarized recent knowledge regarding the use of EVs as natural DDS against CSCs and cancer resistance.
Ayudas:	Instituto de Salud Carlos III PI17/02242 Instituto de Salud Carlos III PI20/01474
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Materia:	Cancer stem cells ; Extracellular vesicles ; Drug delivery systems
Publicado en:	Pharmaceutics, Vol. 12 (november 2020) , ISSN 1999-4923

DOI: 10.3390/pharmaceutics12121146
PMID: 33256036

20 p, 1.8 MB

El registro aparece en las colecciones:
Artículos > Artículos de investigación
Artículos > Artículos publicados